Trials / Withdrawn
WithdrawnNCT04469062
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab IV | Administered IV |
| DRUG | Mirikizumab SC | Administered SC |
| DRUG | Vedolizumab IV | Administered IV |
| DRUG | Placebo IV | Administered IV |
| DRUG | Placebo SC | Administered SC |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2024-03-13
- Completion
- 2024-06-05
- First posted
- 2020-07-13
- Last updated
- 2021-05-06
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04469062. Inclusion in this directory is not an endorsement.